Ten63

Ten63 Therapeutics is a drug discovery company that develops therapeutics for previously undruggable protein targets using its BEYOND platform, the world's first Large Quantum Chemistry Model (LQC). BEYOND achieves quantum-physics levels of accuracy at the speed of classical molecular mechanics, enabling virtual exploration of over 100 trillion molecules per pocket with simulation environments that closely track experimental reality. The platform outperforms Meta's UMA-M on the GMTKN55 leaderboard and achieves significantly lower error rates across drug-like and protein-like systems. Ten63's Superlearning approach pairs generative chemistry with quantum-accurate simulation, creating a compounding path toward drug-discovery superintelligence where each in silico experiment makes the next smarter. The company also operates Sentinel, a virtual CSO that continuously scans public information to propose targets ranked by confidence and patient need. Ten63 is building an internal pipeline of first-in-class and best-in-class programs across oncology. Founded in 2019 and headquartered in Durham, North Carolina, Ten63 has raised $45.0M in Series A funding from investors including Hatteras Venture Partners, Morpheus Ventures, SOSV, Draper, Alexandria, Chugai Venture Fund, and Duke University.

Life Sciences Tech > Research & Development > Drug Discovery > Cheminformatics > Lead Discovery > AI Based > Undruggables

Serial Founder

College Wise > Massachusetts Institute of Technology, Yale University